AngioDynamics (ANGO) Projected to Post Earnings on Thursday

AngioDynamics (NASDAQ:ANGO) is anticipated to release its Q1 2026 results before the market opens on Thursday, October 2nd. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $72.6920 million for the quarter. AngioDynamics has set its FY 2026 guidance at -0.350–0.250 EPS.Individuals are encouraged to explore the company’s upcoming Q1 2026 earningoverview page for the latest details on the call scheduled for Thursday, October 2, 2025 at 8:00 AM ET.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.09. The business had revenue of $80.16 million during the quarter, compared to the consensus estimate of $74.26 million. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%.The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.06) earnings per share. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Stock Down 0.6%

Shares of NASDAQ:ANGO opened at $10.72 on Thursday. The stock has a market cap of $435.55 million, a price-to-earnings ratio of -12.92 and a beta of 0.64. AngioDynamics has a 12-month low of $5.83 and a 12-month high of $13.50. The business’s 50 day moving average is $9.65 and its 200 day moving average is $9.66.

Institutional Trading of AngioDynamics

Hedge funds have recently bought and sold shares of the company. State of Wyoming acquired a new position in shares of AngioDynamics in the 2nd quarter worth approximately $31,000. Tower Research Capital LLC TRC grew its position in AngioDynamics by 359.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 4,268 shares in the last quarter. Manatuck Hill Partners LLC lifted its stake in shares of AngioDynamics by 7.7% in the second quarter. Manatuck Hill Partners LLC now owns 350,000 shares of the medical instruments supplier’s stock worth $3,472,000 after buying an additional 25,000 shares during the last quarter. Massar Capital Management LP acquired a new stake in shares of AngioDynamics in the second quarter worth $278,000. Finally, Engineers Gate Manager LP acquired a new position in AngioDynamics during the 2nd quarter valued at $392,000. 89.43% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ANGO has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of AngioDynamics in a research report on Wednesday, July 16th. Canaccord Genuity Group increased their target price on AngioDynamics from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, July 16th. Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 16th. Finally, Lake Street Capital started coverage on AngioDynamics in a report on Wednesday, July 16th. They issued a “buy” rating and a $24.00 target price on the stock. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $19.00.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.